Recent clinical trials have demonstrated unprecedented advances in the treatment of multiple myeloma with CAR T-cell therapy. This novel approach involves genetically modifying a patient’s T-cells to be more effective at targeting and killing myeloma cells, promising long-term remission.
FOR MORE INFORMATION CLICK HERE ➖
https://www.edhacare.com/treatments/cancer/car-t-cell-therapy
Multiple myeloma is a cancer of the plasma cells that has been hard to treat traditionally, with relapses often occurring after standard therapies. CAR T-cell therapy, however, has shown a marked decrease in the populations of cancerous cells, and patients have entered into long periods of remission. Early-phase trials have shown the potential for this treatment to increase survival rates and improve the quality of life for patients.
This involves extracting T-cells from the patient, modifying them to target myeloma cells, and reintroducing these engineered cells back into the patient. It focuses on antigens unique to myeloma cells; hence, modified T-cells will eliminate cancer with greater ease.
CAR T-cell therapy has become one of the greatest developments in multiple myeloma management as it could result in lasting remission for the patients.
